Stock listing
NASDAQ:LBRX LB Pharmaceuticals Inc Stock
Home listing (NASDAQ) of LB Pharmaceuticals Inc
Follow LB Pharmaceuticals Inc into a list and get an email when it puts out news.
Share price · NASDAQ:LBRX
$38.85 USD -1.21 (-3.0%)
Close on Nov 20, 2026
- Day range
- $38.57 – $40.67 USDNov 20, 2026
- Volume
- 302,942 sharesNov 20, 2026
- Market cap
- $1.26B USDAt the close on Nov 20, 2026 · price × 32.36M shares outstanding
- 52-week range
- $15.19 – $50.16 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $14.95M USDMedian day 354,370 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LBRX · Home | $38.85 USD | -1.21 (-3.0%) | 302,942 | $39.23 | $40.67 | $38.57 | $40.06 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LBRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $38.85 | -1.21 | -3.0% | $39.23 | $40.67 | $38.57 | 302,942 | |
| $40.06 | -0.24 | -0.6% | $40.31 | $41.71 | $38.72 | 356,411 | |
| $40.30 | -2.69 | -6.3% | $43.20 | $44.01 | $38.83 | 396,092 | |
| $42.99 | -0.02 | 0.0% | $43.07 | $43.95 | $42.08 | 597,257 | |
| $43.01 | +0.55 | +1.3% | $42.66 | $43.43 | $41.03 | 330,168 | |
| $42.46 | -2.25 | -5.0% | $44.37 | $44.37 | $41.88 | 438,110 | |
| $44.71 | -0.23 | -0.5% | $45.21 | $45.46 | $44.30 | 341,759 | |
| $44.94 | -0.18 | -0.4% | $44.38 | $45.68 | $43.46 | 377,881 | |
| $45.12 | +3.11 | +7.4% | $43.05 | $45.77 | $41.54 | 472,299 | |
| $42.01 | +3.92 | +10.3% | $38.53 | $42.29 | $38.52 | 476,193 | |
| $38.09 | -2.76 | -6.8% | $41.01 | $41.01 | $38.02 | 354,370 | |
| $40.85 | +0.52 | +1.3% | $41.40 | $41.40 | $38.75 | 365,762 | |
| $40.33 | +1.29 | +3.3% | $39.65 | $41.40 | $39.15 | 245,821 | |
| $39.04 | -0.66 | -1.7% | $40.56 | $40.91 | $38.24 | 466,446 | |
| $39.70 | -0.45 | -1.1% | $40.10 | $41.24 | $39.13 | 429,435 | |
| $40.15 | +0.32 | +0.8% | $39.80 | $40.76 | $39.23 | 400,678 | |
| $39.83 | +0.19 | +0.5% | $39.53 | $40.38 | $38.49 | 201,736 | |
| $39.64 | +0.30 | +0.8% | $39.14 | $40.35 | $38.58 | 236,345 | |
| $39.34 | +0.61 | +1.6% | $41.05 | $41.05 | $38.45 | 275,975 | |
| $38.73 | -0.69 | -1.8% | $39.25 | $39.73 | $38.26 | 188,600 | |
| $39.42 | +0.19 | +0.5% | $39.12 | $41.58 | $38.39 | 230,900 | |
| $39.23 | -1.77 | -4.3% | $41.10 | $41.24 | $39.04 | 247,100 | |
| $41.00 | +2.19 | +5.6% | $38.88 | $41.42 | $38.24 | 388,400 | |
| $38.81 | +2.07 | +5.6% | $36.91 | $40.10 | $36.03 | 588,500 | |
| $36.74 | +0.05 | +0.1% | $36.62 | $37.37 | $36.06 | 724,700 | |
| $36.69 | +2.69 | +7.9% | $34.54 | $37.43 | $34.50 | 976,600 | |
| $34.00 | -0.79 | -2.3% | $34.10 | $35.51 | $33.88 | 362,700 | |
| $34.79 | -1.14 | -3.2% | $36.10 | $36.10 | $34.44 | 296,800 | |
| $35.93 | -1.29 | -3.5% | $37.26 | $37.43 | $34.54 | 491,500 | |
| $37.22 | +2.61 | +7.5% | $35.01 | $38.50 | $35.01 | 642,600 | |
| $34.61 | +0.45 | +1.3% | $33.83 | $35.73 | $33.13 | 440,700 | |
| $34.16 | -0.10 | -0.3% | $34.02 | $36.57 | $34.00 | 385,000 | |
| $34.26 | -0.36 | -1.0% | $35.25 | $35.59 | $33.73 | 432,800 | |
| $34.62 | -2.37 | -6.4% | $36.41 | $36.88 | $34.47 | 494,500 | |
| $36.99 | -0.29 | -0.8% | $37.72 | $38.82 | $36.75 | 388,900 | |
| $37.28 | -1.10 | -2.9% | $38.10 | $38.59 | $37.13 | 278,900 | |
| $38.38 | +1.10 | +3.0% | $37.61 | $39.23 | $37.34 | 437,200 | |
| $37.28 | -0.61 | -1.6% | $37.89 | $38.13 | $36.98 | 713,400 | |
| $37.89 | +0.56 | +1.5% | $37.24 | $38.17 | $36.57 | 534,600 | |
| $37.33 | -0.47 | -1.2% | $37.85 | $38.57 | $36.99 | 398,900 | |
| $37.80 | -1.39 | -3.5% | $39.13 | $39.39 | $37.56 | 413,500 | |
| $39.19 | -3.50 | -8.2% | $42.80 | $42.80 | $38.84 | 481,700 | |
| $42.69 | -0.30 | -0.7% | $43.40 | $43.40 | $41.21 | 244,400 | |
| $42.99 | +0.52 | +1.2% | $42.55 | $43.22 | $41.54 | 310,200 | |
| $42.47 | +0.33 | +0.8% | $42.22 | $42.54 | $41.39 | 531,600 | |
| $42.14 | -0.43 | -1.0% | $43.33 | $43.50 | $41.78 | 314,500 | |
| $42.57 | -0.47 | -1.1% | $43.37 | $43.94 | $42.17 | 231,900 | |
| $43.04 | -1.80 | -4.0% | $44.84 | $44.84 | $42.50 | 320,500 | |
| $44.84 | +0.21 | +0.5% | $44.95 | $45.72 | $44.55 | 242,800 | |
| $44.63 | -1.62 | -3.5% | $46.80 | $47.68 | $44.40 | 208,400 | |
| $46.25 | -1.42 | -3.0% | $47.20 | $47.20 | $45.50 | 174,800 | |
| $47.67 | -1.72 | -3.5% | $49.07 | $49.81 | $47.46 | 190,100 | |
| $49.39 | +0.05 | +0.1% | $48.53 | $49.62 | $47.15 | 301,000 | |
| $49.34 | +1.82 | +3.8% | $47.47 | $49.91 | $47.47 | 206,000 | |
| $47.52 | -1.96 | -4.0% | $48.88 | $48.91 | $46.72 | 282,500 | |
| $49.48 | +2.38 | +5.1% | $47.31 | $49.93 | $46.44 | 518,400 | |
| $47.10 | -0.16 | -0.3% | $47.21 | $48.21 | $46.92 | 202,000 | |
| $47.26 | -0.47 | -1.0% | $47.47 | $47.50 | $46.38 | 386,900 | |
| $47.73 | -0.16 | -0.3% | $47.64 | $49.25 | $46.37 | 230,600 | |
| $47.89 | -0.275 | -0.6% | $48.15 | $48.42 | $47.14 | 256,100 | |
| $48.17 | -0.635 | -1.3% | $48.71 | $48.71 | $47.21 | 244,900 | |
| $48.80 | +0.59 | +1.2% | $48.70 | $50.16 | $48.49 | 217,000 | |
| $48.21 | +0.59 | +1.2% | $47.88 | $49.06 | $46.83 | 252,700 | |
| $47.62 | +0.39 | +0.8% | $47.71 | $48.21 | $46.34 | 225,800 | |
| $47.23 | -1.71 | -3.5% | $48.51 | $48.86 | $46.90 | 194,500 |
- Ticker
- NASDAQ:LBRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Latest deck · Nov 5, 2026
Investor Presentation (November 2026)
Investor deck · 35 slides
Latest news
LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 5, 2026
Closed $42.01 (+10.3%) on Nov 6, 2026
LB Pharmaceuticals to Participate in Upcoming Investor Events
Oct 15, 2026
Closed $36.74 (+0.1%) on Oct 16, 2026
LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress
Oct 10, 2026
Closed $35.93 (-3.5%) on Oct 12, 2026
LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Oct 9, 2026
Closed $35.93 (-3.5%) on Oct 12, 2026
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
Oct 6, 2026
Closed $34.26 (-1.0%) on Oct 6, 2026
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer
Sep 15, 2026
Closed $43.04 (-4.0%) on Sep 15, 2026
LB Pharmaceuticals to Participate in Upcoming September Investor Events
Sep 3, 2026
Closed $49.34 (+3.8%) on Sep 4, 2026
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
Sep 3, 2026
Closed $47.52 (-4.0%) on Sep 3, 2026
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 11, 2026
Closed $45.33 (-1.1%) on Aug 11, 2026
LB Pharmaceuticals Announces $150 Million Private Placement
Jul 29, 2026
Closed $39.00 (+11.6%) on Jul 29, 2026
LB Pharmaceuticals Inc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 29 in the last 12 months · 36 in all · newest Nov 5, 2026 · oldest 2025
- Decks
- 16 decks · latest Nov 5, 2026
Where LB Pharmaceuticals Inc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LBRX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:LBRX | BOATS | United States | USD |
Valuation
Price/book 3.0× against a median of 3.4×: 3rd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $858.7M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.81
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| LB Pharmaceuticals Inc · NASDAQ:LBRX | US$1.26B | US$858.7M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 0.81 |
| Absci Corporation · NASDAQ:ABSI | US$1.30B | US$1.13B | n/a | 758× | n/a | 5.9× | n/a | 0.0× | 3.20 |
| Avalyn Pharma Inc. · NASDAQ:AVLN | US$1.26B | US$946.4M | n/a | n/a | n/a | 3.4× | n/a | 0.0× | 0.12 |
| MannKind Corporation · NASDAQ:MNKD | US$1.24B | US$1.46B | n/a | 3.5× | 309× | n/a | −18.1% | n/a | 1.06 |
| Novavax, Inc. · NASDAQ:NVAX | US$1.23B | US$902.3M | n/a | 2.2× | n/a | n/a | −18.6% | n/a | 1.98 |
| Silence Therapeutics PLC · NASDAQ:SLN | US$1.23B | US$984.6M | n/a | 2,159× | n/a | 5.7× | n/a | 0.0× | 1.07 |
| Ocular Therapeutix, Inc. · NASDAQ:OCUL | US$1.23B | US$774.9M | n/a | 15.4× | n/a | 2.8× | −648.6% | 0.2× | 1.35 |
| Generate Biomedicines, Inc. · NASDAQ:GENB | US$1.22B | US$895.6M | n/a | 28.1× | n/a | 3.2× | −637.0% | 0.2× | 1.90 |
| Taysha Gene Therapies, Inc. · NASDAQ:TSHA | US$1.21B | US$837.4M | n/a | 153× | n/a | 3.4× | n/a | 0.1× | 1.69 |
| Mineralys Therapeutics, Inc. · NASDAQ:MLYS | US$1.21B | US$585.1M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.39 |
| GH Research PLC · NASDAQ:GHRS | US$1.20B | US$841.0M | n/a | n/a | n/a | 3.4× | n/a | 0.0× | 1.28 |
| Median of the others | US$1.23B | US$899.0M | 28.1× | 309× | 3.4× | −327.8% | 0.0× | 1.37 |
Forecasts
8 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 58.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -6.04 · 10 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Heather Turner | Chief Executive Officer, LB Pharmaceuticals |
| Joseph M. Miller | Chief Financial Officer |
| Gad Soffer | Chief Operating and Business Officer |
| Minako Pazdera | General Counsel |
| Christopher Zergebel | Senior Vice President, Clinical Operations |
| Ellen Rose | Senior Vice President, Corporate Affairs |
| James Rawls | Senior Vice President, Regulatory Affairs |
| Richard A. Silva | Senior Vice President, Technical Operations |
| Kaya Pai Panandiker | Chief Commercial Officer |
| Susan G. Kozauer | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Rebecca Luse | Director |
| Rekha Hemrajani | Director |
| Scott Garland | Chairman of the Board, LB Pharmaceuticals |
| Ran Nussbaum | Director |
| Rob Lenz | Member |
| Robert R. Ruffolo | Independent Director |
| William Kane | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +10.3% |
| Q2 2026 | Aug 11, 2026 · Before open | −1.1% |
| Q1 2026 | May 15, 2026 · After close | −6.5% |
| Q4 2025 | Mar 26, 2026 · After close | −2.8% |
| Q3 2025 | Nov 6, 2025 · Before open | −4.3% |
| Q2 2025 | Sep 3, 2025 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 35 slides | Nov 5, 2026 |
| Investor Presentation (October 2026) | Investor deck | 35 slides | Oct 27, 2026 |
| Investor Day (October 2026) | Investor day | 60 slides | Oct 27, 2026 |
| Investor Presentation (August 2026) | Investor deck | 35 slides | Aug 11, 2026 |
| Investor Presentation (August 2026) | Investor deck | 35 slides | Aug 11, 2026 |
| Investor Presentation (January 2025) | Investor deck | 20 slides | January 2025 |
| Investor Presentation (December 2023) | Investor deck | 26 slides | December 2023 |
| Investor Presentation (September 2023) | Investor deck | 26 slides | September 2023 |
| Investor Presentation (June 2023) | Investor deck | 33 slides | June 2023 |
| Investor Presentation (February 2023) | Investor deck | 33 slides | February 2023 |
All 16 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (December 2022) | Investor deck | 33 slides | December 2022 |
| Investor Presentation (October 2022) | Investor deck | 33 slides | October 2022 |
| Investor Presentation (December 2021) | Investor deck | 28 slides | December 2021 |
| Investor Presentation (January 2019) | Investor deck | 30 slides | January 2019 |
| Sachs Bio Capital USA Forum 2018 | Conference | 21 slides | Mar 21, 2018 |
| Technical Presentation (October 2017) | Technical | 13 slides | October 2017 |
Financings
| Raise | Date |
|---|---|
| Private placement of common stock and pre-funded warrants Announced: about US$150M · US$34.94 a share · Leerink Partners +1 Dealers: Leerink Partners, Piper Sandler Buyers: Adage Capital Partners, L.P.; BB Biotech; Caligan Partners; Commodore Capital; Deep Track Capital; Farallon Capital Management; Integral Health Asset Management; Janus Henderson Investors; Spruce Street Capital; StemPoint Capital LP Use of proceeds: Expand LB-102 into new indications such as negative symptoms of schizophrenia and Alzheimer's agitation/psychosis, plus working capital and general purposes | Jul 29, 2026 |
| Private placement of common stock and pre-funded warrants Announced: about US$100M · US$21.17 a share · Leerink Partners +2 Dealers: Leerink Partners, Piper Sandler, Stifel Buyers: Balyasny Asset Management L.P.; Caligan Partners; Commodore Capital; Deep Track Capital; Nantahala Capital; Pivotal bioVenture Partners; Spruce Street Capital; TCGX; Trails Edge Capital Partners Use of proceeds: Fund a Phase 2 trial of LB-102 as adjunctive treatment for major depressive disorder, plus working capital and general corporate purposes | Feb 5, 2026 |
| Public offering of common stock Announced: US$285M · US$15 a share · Leerink Partners +2 Dealers: Leerink Partners (co-lead), Piper Sandler (co-lead), Stifel (co-lead) | Sep 11, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$15.00 a share on Sep 10, 2025.
- Price
- US$15.00 a share
- Shares offered
- 19,000,000 shares of common stock
- Offering size
- US$285 million
- Underwriters' option
- Up to 2,850,000 more shares
- Listing
- LBRX on the Nasdaq Global Market
- Underwriters
- Leerink Partners, Piper Sandler, Stifel · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 20, 2024 |
| Filed publicly | Aug 22, 2025 |
| Amended once | Sep 8, 2025 |
| Shares registered with an exchange | Sep 9, 2025 |
| Declared effective by the SEC | Sep 10, 2025 |
| Final prospectus, with the price | Sep 12, 2025 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 12, 2025 |
| EFFECT · Notice that a registration is effective | Sep 10, 2025 |
| S-1MEF · Registration of more shares for the same offering | Sep 10, 2025 |
| CERT · Exchange's certificate of listing | Sep 10, 2025 |
| CORRESP · Letter to the SEC | Sep 9, 2025 |
| CORRESP · Letter to the SEC | Sep 9, 2025 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 9, 2025 |
| S-1/A · Registration statement, amended | Sep 8, 2025 |
| CORRESP · Letter to the SEC | Sep 3, 2025 |
| CORRESP · Letter to the SEC | Aug 22, 2025 |
All 19 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Aug 22, 2025 |
| UPLOAD · Letter from the SEC | Aug 12, 2025 |
| DRSLTR · Letter to the SEC with a draft | Jul 23, 2025 |
| DRS/A · Draft registration statement, amended | Jul 23, 2025 |
| UPLOAD · Letter from the SEC | Jul 2, 2024 |
| DRSLTR · Letter to the SEC with a draft | Jun 24, 2024 |
| DRS/A · Draft registration statement, amended | Jun 24, 2024 |
| UPLOAD · Letter from the SEC | Jun 17, 2024 |
| DRS · Draft registration statement | May 20, 2024 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 12, 2025
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of revenue | 321.0K | |||
| Gross profit | -321.0K | |||
| Research and development | 16.7M | 51.2M | 7.84M | 1.35M |
| Selling, general and administrative | 13.7M | 13.7M | 3.53M | 1.46M |
| Operating income | -30.4M | -64.8M | -11.4M | -2.81M |
| Depreciation and amortization | 321.0K | 91.0K | 4.00K | 2.00K |
| EBITDA | -30.1M | -64.7M | -11.4M | -2.81M |
| Interest expense | 0 | 4.83M | 2.15M | |
| Income before tax | -25.2M | -63.1M | -6.27M | -14.3M |
| Income tax | 1.00K | 1.00K | 1.00K | 1.00K |
| Net income | -25.2M | -63.1M | -6.28M | -14.3M |
| Earnings per share, basic | -3.13 | -176.15 | -1.77 | -4.05 |
| Earnings per share, diluted | -3.13 | -176.15 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 250.2M | 23.0M | 15.0M | 21.4M |
| Short-term investments | 45.0M | 5.02M | 28.3M | 0 |
| Current assets | 308.4M | 28.9M | 45.6M | 21.5M |
| Property, plant and equipment | 1.58M | 1.86M | ||
| Total assets | 312.9M | 33.5M | 45.7M | 21.5M |
| Accounts payable | 2.13M | 2.32M | 1.39M | 156.0K |
| Current liabilities | 7.44M | 8.11M | 2.61M | 469.0K |
| Long-term debt | 24.1M | |||
| Total debt | 3.57M | 3.70M | 24.1M | |
| Total liabilities | 11.6M | 13.8M | 80.1M | 50.3M |
| Shareholders' equity | 301.3M | -94.6M | -34.5M | -28.8M |
| Shares outstanding | 25.3M | 251.7K | 3.54M | 3.54M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -35.2M | -53.1M | -12.1M | -2.73M |
| Capital spending | -52.0K | -769.0K | -25.0K | 0 |
| Free cash flow | -35.3M | -53.8M | -12.1M | -2.73M |
| Cash from investing | -39.9M | 23.2M | -28.0M | 123.0K |
| Cash from financing | 302.6M | 38.3M | 33.7M | 23.0M |
| Change in cash | 227.5M | 8.50M | -6.42M | 20.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 13, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Oct 6, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Oct 1, 2026 | Offer document | SEC |
All 146 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-3ASR · Registration statement | Oct 1, 2026 | Offer document | SEC |
| 3 · Initial statement of ownership | Sep 24, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Sep 15, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 15, 2026 | Management or board change | SEC |
| 3 · Initial statement of ownership | Sep 14, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Sep 3, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 3, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Aug 11, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Jul 29, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 29, 2026 | Material contract | SEC |
| 424B3 · Prospectus | Jul 22, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 22, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 16, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Jun 10, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 10, 2026 | Management or board change | SEC |
| 144 · Notice of proposed sale | Jun 9, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Jun 9, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 9, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | May 12, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 23, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 15, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Apr 14, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 10, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 10, 2026 | Other filings | SEC |
| S-1 · Registration statement | Apr 6, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 26, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 26, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2026 | Results | SEC |
| 8-K · Current report | Mar 16, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 10, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 5, 2026 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 21, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 21, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 21, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 31, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 13, 2025 | Material contract | SEC |
| 8-K · Current report | Nov 12, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 29, 2025 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Sep 25, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 19, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Sep 19, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 18, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 12, 2025 | Current report | SEC |
| 424B4 · Prospectus | Sep 12, 2025 | Offer document | SEC |
| 3 · Initial statement of ownership | Sep 11, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 11, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 11, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Sep 11, 2025 | Other filings | SEC |
| 3 · Initial statement of ownership | Sep 10, 2025 | Insider trade | SEC |
| S-1MEF · Registration of more shares for the same offering | Sep 10, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Sep 10, 2025 | Offer document | SEC |
| 3 · Initial statement of ownership | Sep 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 10, 2025 | Insider trade | SEC |
| CERT · Exchange's certificate of listing | Sep 10, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 9, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 9, 2025 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Sep 9, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Sep 8, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 3, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 22, 2025 | Other filings | SEC |
| S-1 · Registration statement | Aug 22, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 12, 2025 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Jul 23, 2025 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Jul 23, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jul 2, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Jun 24, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Jun 24, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jun 17, 2024 | Other filings | SEC |
| DRS · Draft registration statement | May 20, 2024 | Offer document | SEC |
| D/A | Jan 10, 2024 | Other filings | SEC |
| D | Sep 21, 2023 | Other filings | SEC |
| D/A | Nov 23, 2022 | Other filings | SEC |
| D | Nov 1, 2022 | Other filings | SEC |
| D | Jul 6, 2022 | Other filings | SEC |
| D | Sep 1, 2020 | Other filings | SEC |
| D | Dec 12, 2018 | Other filings | SEC |
| D | Aug 27, 2018 | Other filings | SEC |
| D | May 29, 2018 | Other filings | SEC |
| D | Apr 6, 2017 | Other filings | SEC |
| D | Dec 15, 2016 | Other filings | SEC |
Cap table
Built by 6ix from LB Pharmaceuticals Inc’s releases · as of Nov 3, 2026
- Common shares
- 32,363,040
- Fully diluted
- 32,363,040
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 32,363,040 | Nov 3, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 3, 2026 | 32,363,040 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Heather Turner Other companies: Avalyn Pharma Inc. (Director · Since at least Apr 29, 2026); Terns Pharmaceuticals, Inc. (Director · Since at least Nov 18, 2024); Lyell Immunopharma, Inc. (Chief General Counsel · Jun 16, 2021 – Mar 16, 2022 · Past); Sangamo Therapeutics, Inc. (EVP, General Counsel & Sec. · Feb 12, 2018 – Feb 25, 2019 · Past); Atara Biotherapeutics, Inc. (Former EVP, GC & Sec. · Feb 6, 2018 – Feb 9, 2018 · Past) | Chief Executive Officer, Director · Since at least Sep 10, 2025 |
| Rekha Hemrajani Other companies: BioAge Labs, Inc. (Director · Since at least Apr 17, 2024); MaxCyte, Inc. (Non-Executive Director · Since at least Jun 29, 2022); ALX Oncology Holdings Inc. (Director · Since at least Jun 15, 2022) | Director · Since at least Sep 10, 2025 |
| Robert Lenz Other companies: NovaBridge Biosciences (Director · Since at least Mar 18, 2026); Neumora Therapeutics, Inc. (Head of R&D · Sep 14, 2023 – Feb 18, 2025 · Past) | Director · Since at least Mar 6, 2026 |
| Ellen Rose Other companies: Lyell Immunopharma, Inc. (Senior Vice President, Communications and Investor Relations · Since at least Dec 7, 2025) | Senior Vice President, Corporate Affairs · Since at least Oct 15, 2026 |
| Ran Nussbaum Other companies: Keros Therapeutics, Inc. (Director · Since at least May 30, 2024) | Director · Since at least Sep 10, 2025 |
| Scott Garland Other companies: ALX Oncology Holdings Inc. (Chairman · Since at least Aug 6, 2026) | Chairman of the Board, LB Pharmaceuticals · Since at least Nov 5, 2026 |
| Christopher Zergebel | Senior Vice President, Clinical Operations · Since at least Jun 30, 2026 |
| Gad Soffer | Chief Business Officer · Since at least Sep 10, 2025 |
| James Rawls | Senior Vice President, Regulatory Affairs · Since at least Oct 14, 2025 |
| Joseph Miller | Chief Financial Officer · Since at least Sep 3, 2026 |
All 21 people
| Person | Seat |
|---|---|
| Kaya Pai Panandiker | Chief Commercial Officer · Since at least Nov 12, 2025 |
| Marc L Panoff | Senior Vice President, Finance · Since at least Sep 10, 2025 |
| Minako Pazdera | General Counsel · Since at least Jan 21, 2026 |
| Panandiker Kaya Kamlesh Pai | Chief Commercial Officer · Since at least Nov 10, 2025 |
| Rebecca Luse | Director · Since at least Nov 5, 2026 |
| Richard A. Silva | Senior Vice President, Technical Operations · Since at least Sep 10, 2025 |
| Robert R. Ruffolo | Independent Director · Since at least Nov 5, 2026 |
| Rob Lenz | Member · Since at least May 12, 2026 |
| Susan G. Kozauer | Chief Medical Officer · Since at least Sep 14, 2026 |
| William Kane | Director · Since at least Mar 26, 2026 |
| Zachary Prensky | Director · Since at least Sep 10, 2025 |
Log in to ask 6ix AI your own questions about LB Pharmaceuticals Inc.